Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cesca Therapeutics nets $10.4mm through follow-on

Executive Summary

Regenerative medicine firm Cesca Therapeutics Inc. netted $10.4mm through the follow-on public sale of 7.53mm units priced at $1.50 each. Together, the units are comprised of 7.53mm common shares and five-year warrants to purchase another 2.26mm shares--one warrant can buy 0.30 of a share--exercisable at $1.55. Some of the proceeds will support clinical development of stem cell candidates for critical limb ischemia, acute myocardial infarction, and bone marrow transplant.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies